Literature DB >> 8090614

Consensus conference: practical applications of Pulmozyme. September 22, 1993.

B W Ramsey1, H L Dorkin.   

Abstract

Mesh:

Substances:

Year:  1994        PMID: 8090614     DOI: 10.1002/ppul.1950170613

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


× No keyword cloud information.
  5 in total

Review 1.  Nebulised bronchodilators, corticosteroids, and rhDNase in adult patients with cystic fibrosis.

Authors:  S P Conway; A Watson
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

2.  Dornase alfa for cystic fibrosis. Patients should not be denied a safe, effective treatment.

Authors:  A Bush; M E Hodson; D M Geddes; M Rosenthal; R Dinwiddie; C Wallis; D E Stableforth; S P Conway; J M Littlewood
Journal:  BMJ       Date:  1995-06-10

3.  Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis.

Authors:  R Suri; R Grieve; C Normand; C Metcalfe; S Thompson; C Wallis; A Bush
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

Review 4.  Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis.

Authors:  H M Bryson; E M Sorkin
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

Review 5.  Nebulised hypertonic saline for cystic fibrosis.

Authors:  Peter Wark; Vanessa M McDonald
Journal:  Cochrane Database Syst Rev       Date:  2018-09-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.